# Medical Question & Answer

**Sample ID**: d3eb2373-ecf4-4263-9dba-50df06da4522
**Dataset Index**: 2177

---

## Question

What is the recommended distance for positioning the Impella below the aortic valve?

---

## Answer

> Let's see… What do we have here? The user is asking about the recommended distance for positioning the Impella inlet below the aortic valve. Let's break this down step-by-step. First, I need to think about model-specific positioning targets because CP and 5.5 have different geometries. Then, I should verify the exact millimeter distances from imaging-based references. Next, I will check for any patient-size adjustments, especially in pediatrics or smaller ventricles. After that, I need to review the consequences of malposition to justify why these distances matter. Finally, I will synthesize clear, model-specific recommendations and confirm outlet position and imaging guidance for verification.

> Let me first confirm that positioning recommendations indeed vary by model and are defined relative to the aortic annulus/valve plane, not just visually by fluoroscopy alone. The CP has a distal pigtail and the 5.5 lacks a pigtail, and both specify that the inlet must rest within the LV cavity with the outlet in the ascending aorta; this model-dependent design difference drives different inlet-to-annulus targets, so I should not assume one number fits all [^112bZToF] [^112bZToF].

> For the Impella CP, wait, let me verify the distance precisely before I commit. The normal imaging appearance for CP places the inlet approximately 3.5 cm below the aortic valve, with the distal pigtail angled toward the LV apex and the outlet in the ascending aorta; this 3.5 cm target is the key distance I need to state [^112bZToF].

> For the Impella 5.5, I need to check the exact recommendation and whether it is measured from the annulus versus cusp tips. The same imaging reference specifies the inlet aspect positioned approximately 5 cm below the aortic annulus, and this is corroborated by operative descriptions in adolescents that generally target about 5 cm from the center of the inlet cage to the aortic annulus; the lack of a pigtail changes the visual cues, so relying on the numeric target and TEE/fluoro confirmation is important [^112bZToF] [^1169qc91].

> But wait, what if the patient is smaller, such as a pediatric case where the LV long axis is shorter. I should confirm whether modest adjustments are reported. A pediatric transinnominate Impella 5.5 case documented TEE confirmation of inflow position at approximately 4.5 cm from the aortic annulus, suggesting that slight reductions from the 5 cm adult target may be appropriate to accommodate patient-specific anatomy while keeping the inlet safely within the LV cavity and away from the mitral apparatus [^1122dpUC].

> Next, I should review why these distances matter clinically rather than just stating numbers. Hold on, let's not jump to conclusions without linking to outcomes: imaging examples show that an inlet sitting at the aortic valve level reflects high/proximal malposition with inadequate LV drainage, and case-based reports underscore that malrotation or malposition can entangle the device or direct it toward the mitral apparatus, leading to suboptimal unloading or structural injury; this reinforces the need to adhere to the 3.5 cm (CP) and ~5 cm (5.5) targets and to verify orientation centrally toward the LV apex [^116rRN84] [^1124pi6f].

> Let me synthesize the answer clearly, but I should double-check I am consistent with the model and the anatomic reference plane. For the Impella CP, target the inlet approximately 3.5 cm below the aortic valve, oriented toward the LV apex with the outlet in the ascending aorta; for the Impella 5.5, target the inlet approximately 5 cm below the aortic annulus, with minor adjustment toward 4.5 cm in smaller patients as anatomy dictates, again ensuring the outlet remains in the ascending aorta and the inlet is centered away from the mitral valve [^112bZToF] [^1169qc91] [^1122dpUC].

> I need to ensure the practical verification steps are explicit. Let me consider intraprocedural imaging: use fluoroscopy and TEE to confirm the inlet-to-annulus distance, central LV positioning, and stable outlet location in the ascending aorta, then adjust as needed; both the CP and 5.5 workflows emphasize active imaging guidance and post-activation fine-tuning to maintain targets and prevent migration or malrotation that could compromise unloading or cause complications [^1169qc91] [^113wvUkj].

---

The Impella inlet should be positioned **3.5–5.0 cm below the aortic valve annulus** [^112bZToF] within the left ventricle, depending on device type: **3.5 cm for Impella CP** and **5.0 cm for Impella 5.5** [^1169qc91]. This placement ensures the inlet is **mid-LV** and the outlet is in the **ascending aorta** [^112bZToF], avoiding contact with the mitral apparatus or LV apex [^116rRN84]. Position is confirmed by **fluoroscopy and echocardiography** [^1169qc91] [^115RwSEs], and malposition increases risks of hemolysis [^notfound], aortic regurgitation [^notfound], and LV injury [^117KBFhH].

---

## Recommended distance below the aortic valve

For the **Impella CP**, the inlet should be positioned approximately **3.5 cm** below the aortic valve annulus [^112bZToF], and for the **Impella 5.5**, approximately **5.0 cm** [^1169qc91], with the outlet in the ascending aorta for both devices [^112bZToF]. These distances ensure the inlet is in the **mid-LV cavity**, away from the mitral apparatus and apex [^1125u45g], and that the outlet lies above the valve in the **ascending aorta** [^112pCj1a].

---

## Clinical significance of correct positioning

Correct positioning is **critical** for optimal function and to minimize complications:

- **Hemodynamic support**: Proper placement ensures effective LV unloading [^112Bg7ZJ] and improved cardiac output [^1135GFxz].

- **Complication prevention**: Correct positioning reduces risks of hemolysis [^1135GFxz], aortic regurgitation [^115km7Pb], and LV injury [^111sHozh].

- **Device performance**: Accurate placement prevents malposition-related alarms and suboptimal support [^1124pi6f].

---

## Imaging modalities for confirmation

Accurate placement is confirmed using **fluoroscopy and echocardiography**: Fluoroscopy provides real-time visualization during insertion and adjustment [^112bZToF], and **Echocardiography** (TEE or TTE) confirms inlet and outlet positions and detects complications [^115RwSEs] [^115km7Pb].

---

## Consequences of incorrect positioning

In cases of **incorrect positioning**, potential consequences include:

- **Hemolysis**: From turbulent flow or contact with cardiac structures [^1135GFxz].

- **Aortic regurgitation**: From valve interference or injury [^115km7Pb].

- **LV injury**: Including perforation or entanglement with papillary muscles [^117KBFhH] [^116rRN84].

- **Suboptimal support**: Reduced unloading and hemodynamic compromise [^1124pi6f].

---

## Summary table: recommended distances

| **Device** | **Recommended distance below aortic valve** |
|-|-|
| Impella CP | 3.5 cm |
| Impella 5.5 | 5.0 cm |

---

The Impella inlet should be positioned **3.5–5.0 cm below the aortic valve annulus**, tailored to device type, to ensure effective support and minimize complications [^112bZToF].

---

## References

### CT and chest radiography in evaluation of mechanical circulatory support devices for acute heart failure [^116rRN84]. Insights into Imaging (2023). Low credibility.

Complications are commonly observed with the Impella pump, including malposition and vascular injury. Fig. 6 and Fig. 7 illustrate instances of malposition, while Fig. 8 demonstrates vascular injury. Rare complications, such as LV perforation, are shown in Fig. 9 and referenced in Additional file 2: Movie S2.

- **Fig. 6: Malposition of Impella pump**: An AP chest radiograph with CLAHE filter (a) depicts an Impella CP device with the outlet port positioned in the aortic arch (white arrow) and the inlet port at the level of the aortic valve (dashed arrow). A contrast-enhanced CT coronal image (b) at the level of the LVOT illustrates high/proximal placement of the Impella device, with the blood inlet port at the level of the aortic valve. Contrast is visible only in the aorta and not in the left ventricle, attributable to backfilling from the VA ECMO cannula in the femoral artery. (CLAHE — contrast limited adaptive histogram equalization, LVOT — left ventricle outflow tract, VA ECMO — veno-arterial extracorporeal membrane oxygenation)

- **Fig. 7: Malposition of Impella device**: An AP chest radiograph with the CLAHE filter (a) reveals a left ventricle Impella device, with its tip projecting over the left ventricle (black arrow). An axial contrast-enhanced CT (b) indicates that the pigtail portion of the Impella device is entangled within the papillary muscle apparatus (black arrow). This finding is not detected on the radiograph but can be identified on a CT. (CLAHE — contrast limited adaptive histogram equalization)

- **Fig. 8: Complication of Impella device**: An axial non-contrast CT in a patient with a transfemoral Impella device demonstrates medial displacement of the intimal calcification, which is consistent with an acute aortic dissection.

---

### Use of microaxial flow pumps in adolescents [^1169qc91]. JTCVS Techniques (2023). Low credibility.

After removal of the wire, positioning of the device in the left ventricle (LV) is assessed with fluoroscopy and transesophageal echocardiography. Generally, the distance from the center of the inlet cage to the aortic valve annulus is approximately 5 cm. After ensuring appropriate positioning, the device is started, and further adjustments to device position are made as needed. The Dacron graft is then cut to the appropriate size, the insertion sheath is advanced, and the device is secured in place. The right subclavian incision is then closed, and sterile dressings are applied.

In cases where the device cannot be placed due to small artery size or acute angulation of the great vessels, options include aborting to left-sided axillary placement, direct aortic placement via partial or full sternotomy, or conversion to venoarterial extracorporeal membrane oxygenation (VA-ECMO) with a cannula placed within the Dacron graft as described in case 3 of this report.

- **Perioperative considerations**: Given that use of the Impella 5.5 is not widespread in the adolescent population, there are several perioperative considerations when caring for these patients. All adolescent patients undergoing non-emergency evaluation for Impella 5.5 therapy received preoperative computed tomography (CT) or ultrasound imaging to exclude aberrant right subclavian artery, which is not uncommon in patients with congenital heart disease. Further, caring for these patients requires nursing staff to be familiar with Impella 5.5 management. Initially, all patients aged less than 18 years with the Impella 5.5 were

---

### CT and chest radiography in evaluation of mechanical circulatory support devices for acute heart failure [^112bZToF]. Insights into Imaging (2023). Low credibility.

The normal imaging appearance of the Impella CP device involves its implantation using fluoroscopy and echocardiography guidance through either the transfemoral or transaxillary approach, employing a 14F sheath. The distal pigtail portion of the Impella CP should be angled toward the left ventricular (LV) apex, away from the mitral valve. The inlet port is ideally positioned about 3.5 cm below the aortic valve, with the outlet port situated in the ascending aorta. The inlet part should be centrally located in the left ventricle, with the distal tip of the Impella pump oriented toward the apex of the left ventricle (Fig. 5).

The Impella 5.5 differs by lacking a pigtail portion. Its inlet aspect should be positioned approximately 5 cm below the aortic annulus. The outlet port of all Impella pumps should always be situated in the ascending aorta. For aortic insertion, the access point is typically located about 7 cm above the aortic annulus.

---

### Post-myocardial infarction ventricular septal rupture bridged to HeartMate 3 with an Impella 5.5 [^112VHMGj]. The Annals of Thoracic Surgery (2021). Low credibility.

Optimal timing of surgical repair for patients diagnosed with a post-myocardial infarction ventricular septal rupture is controversial. Urgent surgical intervention to prevent hemodynamic decompensation must be balanced against delayed repair to allow for tissue stabilization and increased likelihood of a successful outcome.

We report the use of an axillary Impella 5.5 (Abiomed Inc, Danvers, MA), a temporary left ventricular assist device, to aid in hemodynamic stabilization, shunt fraction reduction, and tissue maturation. This approach led to eventual definitive surgical repair in a patient who presented with a post-myocardial infarction ventricular septal rupture and cardiogenic shock.

---

### Feasibility, accuracy, and reproducibility of aortic valve sizing for transcatheter aortic valve implantation using virtual reality [^1131tcqH]. Journal of the American Heart Association (2024). High credibility.

Kamiya et al. evaluated the visualization of the aortic root in a healthy adult and the performance of measurements in virtual reality (VR) based on MSCT data. The detailed visualization might improve the understanding of the form and function of the aortic root. Additionally, an examination of the measurement accuracy compared with a known prosthesis revealed a measurement error of less than 0.5%.

Ruyra et al. investigated these advantages in a prospective, single-center study with 11 patients concerning the value of VR in the procedural planning of TAVI or valve-in-valve interventions. The models were also created using MSCT images. A comparison was made between the decisions following the evaluation of routine clinical images and those made after experiencing VR and intraprocedural findings. VR visualization modified the implant strategy in 45.4% of the cases. VR proved to be a helpful tool, especially in patients with difficult findings. Among other things, it helped assess the distance between the previous bioprosthesis and the coronary ostia before a valve-in-valve procedure or mitral-aortic distance in patients with severe aortic stenosis and previous mechanical mitral valve replacement. Moreover, the confidence of the heart team increased after VR was used to plan interventions. However, the study included only a small number of patients, and no detailed measurements were performed.

Sinha et al. investigated the efficacy of EchoPixel. This software provided an interactive VR platform by rendering volumetric Digital Imaging and Communications in Medicine files, in guiding TAVI device sizing. It showed remarkable potential for enhancing procedural accuracy and decision-making in clinical settings.

---

### 2020 ACC/AHA guideline for the management of patients with valvular heart disease: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines [^1114sDAH]. The Journal of Thoracic and Cardiovascular Surgery (2021). High credibility.

Regarding surgical interventions for aortic stenosis, more specifically with respect to aortic valve replacement, the ACC/AHA 2021 guidelines recommend performing aortic valve replacement in symptomatic patients with combined aortic stenosis and aortic regurgitation and a peak transvalvular jet velocity of at least 4.0 m/s or a mean transvalvular gradient of at least 40 mmHg.

---

### C-THV measures of self-expandable valve positioning and correlation with implant outcomes [^112vEPyK]. Catheterization and Cardiovascular Interventions (2014). Low credibility.

Accurate positioning of the valve device during transcutaneous aortic valve implantation (TAVI) is of crucial importance. The Paieon C-THV navigation system has been designed to correctly guide device deployment during TAVI.

- **Objective**: Using this navigation system, we aimed to determine the correlation between the anatomic measures of the native aortic valve and the deployed self-expandable valve positioning and to explore the impact upon procedural outcomes.

- **Methods**: We analyzed data of 68 patients with severe symptomatic aortic stenosis undergoing TAVI, using the catheter-based Medtronic-CoreValve self-expandable system. Patients were subdivided into two groups according to whether the C-THV system was used (50) or not (18) during the implantation process. Analysis of geometrical outcomes vs. clinical outcomes, including postprocedural electrical conduction defect and/or para-valvular leaks, was performed.

- **Results**: Taking the target implantation line as a reference, relatively lower vs. higher implantations correlated with a higher frequency of any new onset electrical conduction defect (ECD). The mean corresponding distance from the valve inferior edge below the virtual aortic annulus line was 3.0 ± 1.6 mm vs. 1.2 ± 1.3 mm in patients with (38.5%) vs. without any new onset ECD, respectively (P = 0.05). The use of C-THV navigation seemed to correlate with higher valve implants, but it had no impact on the occurrence of postprocedural paravalvular leaks.

- **Conclusions**: Self-expandable valve implants guided by C-THV navigation seem to be associated with more precise outcomes.

---

### 2020 ACC/AHA guideline for the management of patients with valvular heart disease: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines [^114L63PB]. The Journal of Thoracic and Cardiovascular Surgery (2021). High credibility.

Regarding surgical interventions for aortic stenosis, more specifically with respect to aortic valve replacement, the ACC/AHA 2021 guidelines recommend considering aortic valve replacement in asymptomatic patients with severe aortic stenosis (defined as an aortic velocity of ≥ 5 m/s) and low surgical risk.

---

### New anatomically oriented transapical aortic valve implantation [^116PdqGv]. The Annals of Thoracic Surgery (2009). Low credibility.

Transapical aortic valve implantation has become a routine procedure to treat high-risk patients in some centers. To facilitate optimal positioning, a new self-centering valve design with anatomic orientation of the commissures has been developed. This self-expanding nitinol stent-based valve has three support arms that are placed within the aortic sinuses. Here, we report the implantation of this new valve in a patient. The valve demonstrated excellent function with a low transvalvular gradient.

---

### Use of microaxial flow pumps in adolescents [^1125u45g]. JTCVS Techniques (2023). Low credibility.

Impella 5.5 insertion in the adolescent population presents unique operative considerations. Before incision, we inspect with echocardiogram for five key characteristics: (1) left ventricular thrombus, (2) right heart function, (3) significant septal defects, (4) aortic valve competency, and (5) device fit. For device fit, the cage must be inside the ventricle, the outflow must be above the aortic valve, and the device must fit through the aortic valve without occluding coronary or other arterial flow.

Manufacturer contraindications include an aortic valve diameter less than 1.5 cm and a ventricular long-axis length less than 7 cm. A 4- to 6-cm right subclavian incision facilitates exposure of the right axillary artery. After administering 5000 units of heparin, the right axillary artery is clamped. A longitudinal arteriotomy is made, and we anastomose an 8-mm or 10-mm beveled (approximately 45°-60°) Dacron chimney graft to the axillary artery, regardless of the patient's axillary artery diameter. The graft is tunneled superficial to the chest wall muscles and out through a separate incision inferior on the axilla. After clamp removal and ensuring hemostasis at the anastomosis, additional heparin is administered to achieve a goal activated clotting time of greater than 250 seconds.

With the assistance of transesophageal echocardiography and fluoroscopy, a 0.035-inch diagnostic J-wire is manually placed through the graft and advanced to the ascending aorta. An AL-1 catheter advances the J-wire through the aortic valve and into the left ventricle (LV).

---

### Single center first year experience and outcomes with Impella 5.5 left ventricular assist device [^114KubF4]. Journal of Cardiothoracic Surgery (2022). Low credibility.

Our center utilized the Impella 5.5® in the treatment of cardiogenic shock from myocardial infarction and systolic heart failure, as well as in support for high-risk percutaneous coronary intervention and cardiotomy. Despite treatment, cardiogenic shock can lead to inadequate cardiac output, causing end organ failure with a high mortality rate of approximately 40%. With the use of the Impella 5.5® for cardiogenic shock, our center had a 75% survival rate to hospital discharge with native heart recovery, durable LVAD implantation, or cardiac transplant. Our center's overall improvement in survival to hospital discharge confirms that the Impella 5.5® is a valid choice for the treatment of cardiogenic shock.

Furthermore, our center's experience highlights the Impella 5.5®'s ability to unload the increased pressures of the heart to reverse organ damage. Hemodynamic monitoring showed improvement in biventricular cardiac filling pressures, which correlated with the improvement seen on echocardiography.

Improved organ perfusion was confirmed with laboratory monitoring before, during, and after the use of the Impella 5.5®. Lactate levels, BUN/creatinine, and liver enzyme studies all decreased with Impella 5.5® use. The initial worsening of creatinine and liver enzyme studies are expected, as both biomarkers can lag upwards of 3–4 days after the reversal of cardiogenic shock. Both hemoglobin and platelet levels decreased during Impella 5.5® implantation; however, no patient experienced an iatrogenic sudden decrease in these levels, suggesting minimal cellular shearing by the device. In addition, platelet counts stabilized.

---

### 2020 ACC/AHA guideline for the management of patients with valvular heart disease: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines [^114cbr3V]. The Journal of Thoracic and Cardiovascular Surgery (2021). High credibility.

Regarding surgical interventions for aortic stenosis, specifically concerning aortic valve replacement (choice of valves), the ACC/AHA 2021 guidelines recommend choosing a prosthetic valve based on a shared decision-making process. This process should account for the patient's values and preferences, including a discussion of the indications for and risks of anticoagulant therapy, and the potential need for and risks associated with valve reintervention in patients with an indication for aortic valve replacement.

---

### Positioning of self-expanding transcatheter valve prostheses [^113Jwgr8]. Catheterization and Cardiovascular Interventions (2019). Low credibility.

The anatomic interplay between the aortic valve, ascending aorta, left ventricular outflow tract, and peripheral vasculature plays a major role in determining device-related outcomes in transcatheter aortic valve replacement. Factors such as the alignment angle (prosthesis-ascending aorta), pre-dilatation, operating team experience, and chronic kidney disease may influence valve displacement. Careful analysis of all imaging modalities while sizing and selecting a valve type, as well as attention to newer deployment techniques, may improve outcomes.

---

### Color doppler artifact masking iatrogenic aortic valve injury related to an Impella device [^115km7Pb]. Journal of Cardiothoracic and Vascular Anesthesia (2019). Low credibility.

The Impella (Abiomed, Danvers, MA) is a minimally invasive transvalvular left ventricular assist device (LVAD) that effectively unloads the left ventricle (LV), especially in patients with ventricular arrhythmias in the setting of a venous-arterial extracorporeal membrane oxygenator (VA ECMO). Utilization of the Impella device has increased significantly in the last few years for high-risk percutaneous coronary intervention and cardiogenic shock due to its relatively easy implantation in the catheterization lab and operating room.

Although rare, iatrogenic injury of the aortic valve (AV) can be caused by placement of the device across the AV, leading to aortic regurgitation (AR) with significant clinical consequences in the setting of cardiogenic shock. This AR can be challenging to diagnose echocardiographically because of the artifacts generated by the device when using color-flow Doppler. In this E-challenge, the authors emphasize the importance of recognizing these findings for accurate interpretation of the echocardiogram in the management of cardiogenic shock refractory to the Impella LVAD and the utility of transesophageal echocardiography (TEE).

---

### Use of Impella heart pump for management of women with peripartum cardiogenic shock [^117A91eE]. Clinical Cardiology (2019). Low credibility.

Percutaneous MCS devices are increasingly used in the treatment of CS. The Impella devices are transvalvular micro-axial flow pumps that entrain blood from the LV and pump it into the aorta in series, thus unloading the LV. These devices are a valuable tool in the management of CS due to their ability to maintain vital organ perfusion, decrease LV wall stress, and myocardial oxygen consumption, thereby enhancing the likelihood of ventricular recovery. In fact, multiple studies have demonstrated that early initiation of Impella support within 90 minutes of CS onset is associated with higher survival. An additional advantage of early Impella use in CS is the decrease in the use of inotropic agents, thus reducing the effects of these cardiotoxic drugs. In comparison to the growing evidence base of the benefits of Impella support in CS due to myocardial infarct, very few reports exist on the use of Impella in CS due to PPCM.

In this study, the majority of women were diagnosed with PPCM post-delivery with a mean LVEF of 14%. This group was previously shown to have a low likelihood of recovery. In addition, most of the women in the present study were in CS and received mechanical ventilation and inotropic support. Despite the critically ill nature of these women, over 85% survived to discharge, and 1 in 2 women had recovery of their native heart function. This demonstrates the potential of MCS with Impella for hemodynamic stabilization and as a bridge to recovery or implantation of a durable cardiac assist device in women with CS due to PPCM.

---

### Novel strategy for postcardiotomy support in a patient with adult congenital heart disease [^1125siBN]. JTCVS Techniques (2023). High credibility.

Figure 1 shows a three-dimensional printed model used for determining the position of the Impella 5.5 device (Abiomed Inc). Figure 2 presents a model of the Impella 5.5 device (Abiomed Inc) positioned across the native aortic valve and the ventricular septal defect.

---

### 2020 ACC/AHA guideline for the management of patients with valvular heart disease: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines [^115Mm4WL]. The Journal of Thoracic and Cardiovascular Surgery (2021). High credibility.

Concerning the medical management for prosthetic heart valves, specifically regarding anticoagulant therapy after surgical mechanical prosthesis implantation, the ACC/AHA 2021 guidelines recommend initiating vitamin K antagonists (VKAs) to achieve an INR of 2.5 in patients with a mechanical bileaflet or current-generation single-tilting disk aortic valve replacement and no risk factors for thromboembolism.

---

### MDCT evaluation of aortic root and aortic valve prior to TAVI: What is the optimal imaging time point in the cardiac cycle [^111xEQLF]. European Radiology (2015). Low credibility.

The following measurements of the aortic root and the aortic valve were performed using MPRs according to the Society of Cardiovascular Computed Tomography (SCCT) expert consensus guidelines: (1) short annulus diameter; (2) long annulus diameter; (3) area, defined as an oval or ring formed by linking the most basal portions of the leaflet attachments; (4) annulus circumference; (5) distance from the aortic annulus to the center of the ostium of the right coronary artery; (6) distance from the aortic annulus to the center of the ostium of the left coronary artery; (7) sinotubular junction diameter; (8) aortic root diameter at the level of the right coronary artery ostium; (9) aortic root diameter at the level of the left coronary artery ostium; (10) widest portion of the coronary sinuses diameter; (11) left aortic valve leaflet length; and (12) right aortic valve leaflet length, including distances from the leaflet basal insertion to the free edge.

Fig. 1 illustrates examples of particular measurements of aortic root and aortic valve dimensions: (a) the aortic annulus; (b) the annulus to the right coronary artery ostium; (c) the annulus to the left coronary artery ostium; and (d) the length of the right coronary leaflet.

The mean diameter (13) was defined as the average of short and long diameters of an aortic annulus; circumference-derived diameter (14) was defined as circumference/π; and the effective diameter (15) was defined by the following formula:

The following parameters were used in the assessment of annulus shape: aortic annulus sphericity ratio (16) (AASR = long dia…

---

### Single center first year experience and outcomes with Impella 5.5 left ventricular assist device [^111kMp3c]. Journal of Cardiothoracic Surgery (2022). Low credibility.

The summary of our experience with Impella 5.5® can expand the overall understanding of its use to achieve successful patient outcomes, as well as provide support for the expansion of its FDA-approved use. In addition, our experience highlights a bias in mechanical circulatory support against the female sex and minority groups, which is under-recognized and not fully understood. We are hopeful that our experience can help improve outcomes at other centers in their comprehensive care for cardiogenic shock.

---

### Incidence and prognosis of vascular complications after percutaneous placement of left ventricular assist device [^111JDcmu]. Journal of Vascular Surgery (2015). Low credibility.

Mechanical assist devices have found an increasingly important role in high-risk interventional cardiac procedures. The Impella (Abiomed Inc, Danvers, Mass) is a percutaneous left ventricular assist device inserted through the femoral artery under fluoroscopic guidance and positioned in the left ventricular cavity. This study was undertaken to assess the incidence of vascular complications and associated morbidity and mortality that can occur with Impella placement.

- **Methods**: We used a prospective database to review patients who underwent placement of an Impella left ventricular assist device in our tertiary referral center from July 2010 to December 2013. Patient demographics, comorbidities, interventional complications, and 30-day mortality were recorded.

- **Results**: The study included 90 patients (60% male). The mean age was 66 years (range, 17–97 years). Hypertension was found in 69% of the patients, 37% were diabetic, 57% had a history of tobacco abuse, and 65% had chronic renal insufficiency. The median pre-procedure cardiac ejection fraction was 30%. Most (87%) had undergone coronary artery intervention. Cardiogenic shock was documented in 67 patients (74%). The Impella was placed for an average of 1 day (range, 0–5 days). At least one vascular complication occurred in 15 patients (17%). Acute limb ischemia occurred in 12 patients, of whom four required an amputation and six required open or endovascular surgery. Other complications included groin hematomas and one pseudoaneurysm. All-patient 30-day mortality was 50%, which was not significantly associated with vascular complications.

---

### Surgically implanted endovascular, microaxial left ventricular assist device: A single institution study [^111rnzR9]. JTCVS Techniques (2024). High credibility.

The Impella 5.5 (Abiomed, Inc.), a surgically implanted endovascular microaxial left ventricular assist device, is increasingly used worldwide, with more than 10,000 implants. The purpose of this study is to describe a large-volume, single-center experience with the use of the Impella 5.5.

Data were obtained retrospectively from patients supported with the Impella 5.5 implanted at our institution from May 1, 2020, to December 31, 2022. Demographic, operative, and postoperative outcomes for each group are described. Results are reported in median (interquartile range) or n (%). The entire cohort was divided into five main groups based on the intention to treat at the time of the Impella 5.5 implantation:

- **High-risk cardiac surgery**: Patients who had a planned Impella 5.5 implanted at the time of high-risk cardiac surgery.
- **Cardiogenic shock**: Patients with cardiogenic shock.
- **Bridged to durable device**: Patients bridged to a durable left ventricular assist device.
- **Bridged to transplant**: Patients bridged to transplant.
- **Postcardiotomy shock**: Patients with postcardiotomy shock who received an unplanned Impella 5.5 implant.

A total of 126 patients were supported with the Impella 5.5. Overall survival to device explant was 76.2%, with 67.5% surviving to discharge. Midterm survival was assessed with a median follow-up time of 318 days, demonstrating an overall survival of 60.3% and a median of 650 days (549–752). Outcomes after using the Impella 5.5 vary depending on the indication of use. Patient selection may be of utmost importance and requires further experience with this device to determine who will benefit most.

---

### Left ventricular unloading using an Impella CP improves coronary flow and infarct zone perfusion in ischemic heart failure [^112Bg7ZJ]. Journal of the American Heart Association (2018). Low credibility.

Patients who survive myocardial infarction (MI) often develop signs of heart failure (HF) in the subacute MI setting, which appear within 2 to 4 weeks after MI and are associated with worse clinical outcomes. Treatment paradigms make use of medical therapies to hemodynamically stabilize these patients, but they are limited in fundamentally improving native heart function. In fact, 25% of patients develop clinical HF within 1 year of the index MI event, and 75% will do so within 5 years. Preventing the development of HF in patients after MI poses a substantial challenge, and new therapeutic approaches are needed.

Catheter-based left ventricular (LV) unloading has become a realistic option for treating patients with MI complicated by cardiogenic shock and progressive HF. Impella is among the most frequently used devices in interventional clinics, and emerging data have suggested that LV unloading with an Impella during acute MI may reduce reperfusion injury and final infarct size. However, mechanical LV unloading may also have a therapeutic impact beyond the acute MI setting.

In addition to increasing cardiac output and providing hemodynamic stability, Impella actively aspirates blood directly from the LV into the aorta. This decreases LV end-diastolic wall stress (EDWS) by reducing both the size and the pressure of the LV dramatically. Increased wall stress is a pathological feature of HF and is a well-established stimulus for maladaptive ventricular remodeling after MI, including hypertrophic responses and remodeling.

---

### Left ventricular unloading in nonischemic dilated cardiomyopathy improves coronary haemodynamic reserve [^113W61wG]. Catheterization and Cardiovascular Interventions (2025). Low credibility.

The Impella CP (Abiomed, USA) is a catheter-based ventricular assist device commonly utilized in the management of cardiogenic shock and to support high-risk percutaneous coronary interventions (PCI). It is typically delivered via large bore femoral artery access into the left ventricle, where it aspirates and pumps blood into the ascending aorta at a rate between 2.5 and 5 L per minute. In addition to providing additional cardiac output, the Impella CP improves coronary haemodynamics by increasing distal coronary pressure and by decreasing left ventricular end-diastolic pressure and left ventricular wall stress.

---

### Transcatheter aortic valve with a novel self-expandable device in patients with previous mechanical mitral valve prosthesis [^111aJTwm]. Catheterization and Cardiovascular Interventions (2022). High credibility.

The aim of this study was to describe the procedural and early outcomes of patients with mechanical mitral valve prosthesis (MVP) undergoing transcatheter aortic valve replacement (TAVR) with a novel self-expandable retrievable device.

- **Background**: TAVR in patients with prior MVP may have an increased risk of complications related to device positioning and interference between both prosthetic valves.

- **Methods**: An observational study was conducted, including eight patients with severe symptomatic aortic stenosis and prior mechanical MVP who underwent TAVR with the novel device Allegra TM (Biosensors). No transesophageal monitoring was used.

- **Results**: The mean age of the study population was 75 years. The mean distance between MVP and aortic annulus was 3.8 mm. Procedural success was achieved in all patients with no major intraprocedural, in-hospital, or follow-up complications.

- **Conclusions**: TAVR with the Allegra TAVI system in patients with prior MVP offers good procedural and clinical outcomes.

---

### CT and chest radiography in evaluation of mechanical circulatory support devices for acute heart failure [^111EQQVF]. Insights into Imaging (2023). High credibility.

Impella RP

- **Indication and mechanism**: Impella RP (Abiomed Inc. MA, USA) is a micro-axial flow percutaneous MCS device, positioned from a single femoral venous access. It traverses the tricuspid and pulmonary valves. The outlet is positioned above the pulmonary valve in the main or the left pulmonary artery. Impella RP can deliver flow up to 4 L/min. This device cannot be used to oxygenate blood.

In the RECOVER RIGHT trial, the central venous pressure and cardiac index improved after Impella RP implantation, allowing weaning of inotrope and vasopressor support. A recent prospective study at 14 US institutions in patients with life-threatening RV failure demonstrated rapid reversal of shock and favorable survival after Impella RP support.

- **Normal imaging appearance**: This device uses a 22 F impeller mounted onto an 11 F catheter. The inlet port should be in the right atrium or inferior vena cava, and the pigtail portion should be positioned in the main pulmonary artery. When Impella RP is not available, the Impella CP or 5.5 have been used with reversal of flow direction.

A chest radiograph with CLAHE filter in a patient with an Impella RP for right ventricle support shows the pigtail portion in the outflow is in the main pulmonary artery, and the inlet is in the IVC (CLAHE — contrast limited adaptive histogram equalization, IVC — inferior vena cava).

A chest radiograph demonstrates a right-sided placement of a LV Impella 5.5 placed intraoperatively through a pulmonary artery graft. The inflow is located in the right ven.

---

### Ct and MR imaging prior to transcatheter aortic valve implantation: standardisation of scanning protocols, measurements and reporting-a consensus document by the European Society of Cardiovascular Radiology (ESCR) [^116uJHhk]. European Radiology (2020). Low credibility.

The largest dimensions of the aortic sinus and sinotubular junction should be assessed on a double-oblique projection. The sinus of Valsalva acts as a reservoir for the displaced native aortic valve calcifications after device deployment. The required dimensions of the aortic sinus are specified by the manufacturer of the specific device to be implanted and vary from model to model.

- **Determination of optimal c-arm angulation**: There is a remarkable individual variation in the anatomic position of the aortic valve. It typically projects with slight caudal angulation in the right anterior oblique (RAO) projection and cranial angulation in the left anterior oblique (LAO). During the procedure, the correct tube projection must be determined to establish the optimal fluoroscopic orientation consistent with an orthogonal view of the aortic valve plane. This view should have the origin of the right coronary artery pointing towards the viewer, with the inferior margins of the three coronary cusps projecting at equal size and distance from each other. The right coronary cusp should be in the middle, the left coronary cusp to the left, and the non-coronary cusp to the right. Without 3D imaging guidance, achieving this view would require multiple aortograms, thus increasing procedural time as well as the contrast volume, potential for contrast-induced nephrotoxicity, and radiation dose.

However, imaging-based prediction of the correct aortic annulus angle projection can reliably improve procedural outcomes and reduce risks.

---

### Use of Impella heart pump for management of women with peripartum cardiogenic shock [^111ZxgBg]. Clinical Cardiology (2019). Low credibility.

- **Methods**: The study is a retrospective analysis of 15 patients with peripartum cardiomyopathy (PPCM) undergoing left ventricular (LV) unloading with Impella devices between November 2008 and October 2015, identified in the global cVAD registry. Of the 15 patients, five were treated at Hannover Medical School (a cVAD site) and have been previously described. The remaining patients were enrolled at eight cVAD sites within the United States. The global cVAD registry is an ongoing registry of patients who received Impella support or attempted support in North America and Europe since the inception of the registry in 2009. The cVAD Registry was designed by an Executive Steering Committee that oversees its ongoing conduct. The registry protocol was reviewed and approved by the Institutional Review Board at each participating site. Sites are invited to report all consecutive Impella cases without pre-selection of indication or patients. To avoid patient selection bias, a process was developed to reconcile the site's utilization of the device (commercial database) with reporting in the clinical cVAD registry. Patients identified as having received an Impella device in the commercial database were expected to be reported in the cVAD Registry database; otherwise, sites were notified of the obligation to enter and report the cases to ensure consecutiveness.

- **Patient treatment and follow-up**: Data were abstracted from the medical record to a standard electronic case report form by the sites' study coordinators, who were centrally trained. Information was collected and entered into the database to ensure the accuracy and completeness of the records.

---

### Echo-guided presentation of the aortic valve minimises contrast exposure in transcatheter valve recipients [^115q9q6v]. Catheterization and Cardiovascular Interventions (2011). Low credibility.

We have developed a method using transthoracic echocardiography to establish optimal visualization of the aortic root, aiming to reduce the amount of contrast medium used in each patient.

During transcatheter aortic valve implantation, it is crucial to obtain an optimal fluoroscopic projection for valve deployment that shows the aortic ostium with the three cusps aligned in the beam direction. This often requires repeat aortic root angiograms at this stage of the procedure, which involves a high amount of contrast medium, posing a risk of detrimental impact on renal function.

We studied both the conventional and an echo-guided way to optimize visualization of the aortic root. Echocardiography was used initially, allowing easier alignment of the image intensifier with the transducer's direction.

Contrast volumes, radiation/fluoroscopy exposure times, and postoperative creatinine levels were significantly less in patients having the echo-guided orientation of the optimal fluoroscopic angles compared with patients treated with the conventional approach.

We present a user-friendly echo-guided method to facilitate fluoroscopy adjustment during transcatheter aortic valve implantation. In our series, the amounts of contrast medium and radiation have been significantly reduced, along with a concomitant reduction in detrimental effects on renal function in the early postoperative phase.

---

### Novel technique of performing multivessel PCI through an Impella sheath [^114BhhXe]. Catheterization and Cardiovascular Interventions (2020). Low credibility.

A 69-year-old woman with diabetes was found to have multivessel coronary artery disease and underwent 5-vessel coronary artery bypass grafting. The patient experienced persistent cardiogenic shock postoperatively, despite the use of an intra-aortic balloon pump and escalating pressor requirements. Electrocardiogram results indicated new ischemic changes, prompting an urgent transfer to the catheterization lab for coronary angiography and the placement of an Impella CP for higher-grade hemodynamic support via the left femoral artery.

Due to limitations in vascular access, the Impella CP sheath was utilized for both diagnostic angiography and coronary intervention concurrently with ongoing Impella CP support. The first obtuse marginal had severe proximal disease and was treated with percutaneous coronary intervention (PCI) using a drug-eluting stent. To our knowledge, this case represents the first successful diagnostic angiography and multivessel PCI performed via an Impella sheath while concurrently using the percutaneous mechanical circulatory support system of the Impella CP.

Multiple guide catheters and a pigtail catheter were successfully passed via the Impella CP sheath to perform PCI. This novel method of vascular access could be an important tool for high-risk patients with limited access sites and potentially decrease bleeding complications by limiting the number of arterial punctures.

---

### 2020 ACC/AHA guideline for the management of patients with valvular heart disease: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines [^114EZHGd]. The Journal of Thoracic and Cardiovascular Surgery (2021). High credibility.

Regarding surgical interventions for aortic stenosis, more specifically with respect to aortic valve replacement (choice of valves), ACC/AHA 2021 guidelines recommend considering the use of a bioprosthesis over a mechanical valve in patients older than 65 years of age requiring aortic valve replacement.

---

### Percutaneous reduction of septal-to-lateral mitral annular distance to increase mitral leaflet coaptation length: Preclinical study results [^113ebdMd]. JTCVS Techniques (2023). High credibility.

The subject of this study, the **materials and methods**, involves a device characterized by a unique design that mimics an anchor. The device is composed of three key elements:

- **Device description**: The first element, known as the "saddle", is inserted into the coronary sinus. The second element, the "plug", is positioned in the left ventricular outflow tract (LVOT), situated just below the junction of the noncoronary and left coronary leaflets of the aortic valve, referred to as the "aortic-mitral curtain". The third element is the "bridge", which connects the saddle and the plug. The bridge's length can be adjusted to effectively reduce the septal-to-lateral mitral annular distance. Both the saddle and plug are constructed from stainless steel, while the bridge is made from expanded polytetrafluoroethylene (ePTFE).

A detailed schematic illustration of the device is presented in Figure 1. It consists of a T-shaped metallic element, the saddle (A), which is placed in the great cardiac vein (GCV); a retaining metallic element, the plug (B), positioned within the LVOT just below the aortic valve in the aortic-mitral curtain; and a connecting element made of ePTFE, the bridge (C), that links the two elements by pulling the saddle toward the plug.

---

### Alternative implantation technique for rapid deployment valve [^114zxqwu]. The Annals of Thoracic Surgery (2019). Low credibility.

We present a simpler and faster way of implanting the Edwards Intuity Elite rapid deployment valve system. Annular sizing and guiding suture placement are performed in the usual manner. After the valve is parachuted down to the annulus, the balloon catheter is detached, and a vent catheter is placed through the center hole to maximize exposure of the valve. The guiding sutures are tied down using an automated suture fastening device instead of securing snares. Visualization of the tip of the suture fastener on the annulus ensures proper valve seating. The sealing frame is ballooned, and the valve is deployed.

---

### Crossing boundaries: Utilizing left-sided Impella for right ventricular mechanical support and intraoperative transesophageal echocardiogram considerations [^113wvjXd]. Journal of Cardiothoracic and Vascular Anesthesia (2025). Low credibility.

Right ventricular failure is a leading cause of mortality among patients with various etiologies of cardiogenic shock. This case series outlines an innovative approach to directly unloading the right ventricle with the Impella LD or 5.5 without crossing the tricuspid valve in cases requiring tricuspid valve repair or replacement.

- **Design**: Retrospective single-center review.

- **Setting**: Single tertiary care university hospital.

- **Participants**: Patients who underwent Impella LD or 5.5 insertions for right ventricular support.

- **Interventions**: Impella LD or 5.5 inserted directly into the right ventricle via the pulmonary artery.

- **Measurements and main results**: Patients' baseline, intraoperative, and immediate postoperative clinical and echocardiographic data were obtained. Of the five consecutive patients with severe preoperative right ventricular failure who underwent surgical tricuspid valve procedures and Impella placement, three of the patients underwent concomitant left heart procedures. The Impella was preemptively inserted before separation from cardiopulmonary bypass in all patients. Four patients were extubated within the first 24 hours and ambulated with the Impella by postoperative day (POD) 3. By POD 10, four patients had sufficient right ventricular recovery to allow for Impella LD explant. One patient died due to septic shock with the right ventricular assist device still in place. One patient was transitioned to comfort measures 29 days after explant of the Impella device.

Conclusions indicate that left-sided Impella can be used to support the right ventricle in patients.

---

### MDCT evaluation of aortic root and aortic valve prior to TAVI. What is the optimal imaging time point in the cardiac cycle [^112Wff93]. European Radiology (2015). Low credibility.

To determine the optimal imaging time point for transcatheter aortic valve implantation (TAVI) therapy planning, we conducted a comprehensive evaluation of the aortic root. A multidetector-row CT (MDCT) examination with retrospective ECG gating was retrospectively performed in 64 consecutive patients referred for pre-TAVI assessment. Eighteen different parameters of the aortic root were evaluated at 11 different time points in the cardiac cycle. Time points at which maximal (or minimal) sizes were determined, and dimension differences to other time points were evaluated. Theoretical prosthesis sizing based on different measurements was compared.

The largest dimensions were found between 10 and 20% of the cardiac cycle for the annular short diameter (10%); mean diameter (10%); effective diameter and circumference-derived diameter (20%); distance from the annulus to the right coronary artery ostium (10%); aortic root at the left coronary artery level (20%); aortic root at the widest portion of the coronary sinuses (20%); and right leaflet length (20%). Prosthesis size selection differed depending on the chosen measurements in 25–75% of cases.

Significant changes in the anatomical structures of the aortic root during the cardiac cycle are crucial for TAVI planning. Imaging in systole is mandatory to obtain maximal dimensions.

- **Key points**: Most aortic root structures undergo significant dimensional changes throughout the cardiac cycle. The largest dimensions of aortic parameters should be determined to optimize TAVI. Circumference-derived diameter showed maximum.

---

### Prediction of optimal deployment projection for transcatheter aortic valve replacement: Angiographic 3-dimensional reconstruction of the aortic root versus multidetector computed tomography [^114W8P7a]. Circulation: Cardiovascular Interventions (2012). Low credibility.

Identifying the optimal fluoroscopic projection of the aortic valve is crucial for successful transcatheter aortic valve replacement (TAVR). Various imaging modalities, including multidetector computed tomography (MDCT), have been proposed for predicting the optimal deployment projection. We evaluated a method that provides 3-dimensional angiographic reconstructions (3DA) of the aortic root for predicting the optimal deployment angle and compared it with MDCT.

- **Methods and results**: Forty patients undergoing transfemoral TAVR at St. Paul's Hospital, Vancouver, Canada, were evaluated. All underwent preimplant 3DA, and 68% underwent preimplant MDCT. Three-dimensional angiographic reconstructions were generated from images of a C-arm rotational aortic root angiogram during breath-hold, rapid ventricular pacing, and injection of 32 mL contrast medium at 8 mL/s. Two independent operators prospectively predicted perpendicular valve projections. The implant angle was chosen at the discretion of the physician performing TAVR. The angles from 3DA, from MDCT, the implant angle, and the postdeployment perpendicular prosthesis view were compared. The shortest distance from the postdeployment perpendicular prosthesis projection to the regression line of predicted perpendicular projections was calculated. All but one patient had adequate image quality for reproducible angle predictions. There was a significant correlation between 3DA and MDCT for prediction of perpendicular valve projections (r = 0.682, P < 0.001). Deviation from the regression line of predicted angles was noted.

---

### Reimplantation valve-sparing aortic root replacement is the most durable approach to facilitate aortic valve repair [^1134m8Yc]. JTCVS Techniques (2021). High credibility.

The three cusps must coapt centrally inside the graft and at least 8 to 10 mm above the aortic annulus. Elongated free margins are shortened by plicating centrally along the nodule of Arantius, as shown in the upper panel. The free margin of cusps with large stress fenestration is reinforced with a double layer of 7–0 expanded polytetrafluoroethylene suture, one above and the second a millimeter or two beneath the free margin (lower panel).

Sometimes we overestimate the size of the graft, and one or more cusps barely touch the others centrally, as illustrated in the upper panel of Figure 7. If this occurs, we plicate the Dacron graft in the center of the intercommissural distance, at the level of the new sinotubular junction, as illustrated in Figure 7. This plication extends 2 or 3 mm above and below the sinotubular junction, and the fold in the graft should be on the outside. Geometrically speaking, for every 3 mm of horizontal plication, the diameter of the graft is reduced by 1 mm.

If one or more cusps do not easily reach the central portion of the graft to coapt with the others, the intercommissural distance can be shortened by plicating the graft from the outside, as shown in the upper panel. This creates a neoaortic sinus. The complete repair is illustrated in the lower panel.

Once the reconstruction of the aortic root is completed, we clamp the graft and inject cold blood cardioplegia under high pressure (100 mm Hg) and observe the unvented left ventricle. It has been our experience that a mild degree of AI causes ventricular distension.

---

### Novel strategy for postcardiotomy support in a patient with adult congenital heart disease [^116Wf9Te]. JTCVS Techniques (2023). Low credibility.

The technical skillset required for Impella 5.5 device insertion merits special attention in complex intracardiac anatomy, such as in this case. Of first consideration was the assessment of the patient's vascular anatomy. This consisted of preoperative computed tomography scanning, which confirmed the presence of a patent right axillary artery measuring 7 mm in diameter, deemed adequate for Impella 5.5 device placement.

To facilitate the planning of Impella 5.5 device placement in complex anatomy, and in particular, to determine the intracardiac path of the device, we performed 3-dimensional (3D) printing of a cardiac model based on radiological imaging (Figure 1). This 3D model allowed for presurgical planning for advancement of the Impella 5.5 device to traverse the right axillary and brachiocephalic arteries, the ascending aorta, the native aortic valve, the rudimentary right ventricle, the bulbuventricular foramen, and its final placement in the center of the dilated LV cavity at an Impella length of 5.5 cm (Figure 2).

This was reproduced intraoperatively by anastomosing a beveled 8-mm Gelweave graft (Terumo Medical Corporation) to the right axillary artery, exposed by a lateral infraclavicular incision and division of the pectoralis major and minor muscles. An AL-1 catheter (Terumo Medical Corporation) was then advanced, backloaded with a 0.035 J-Wire (Terumo Medical Corporation), under fluoroscopic guidance into the LV cavity, followed by a changeover to the 0.018 Impella wire. Due to the direct approach required for accurate device placement, the initial gu…

---

### Maintenance of valvular integrity with Impella left heart support: Results from the multicenter PROTECT II randomized study [^115wtgMD]. Catheterization and Cardiovascular Interventions (2018). High credibility.

The Impella 2.5 axial flow pump, which is positioned across the aortic valve, is widely employed for hemodynamic support. The present study compared the structural and functional integrity of the left heart valves in patients undergoing Impella versus intra-aortic balloon pump in the randomized PROTECT II trial.

- **Methods and results**: Transthoracic echocardiograms were performed at baseline, 1 and 3 months in 445 patients in the PROTECT II trial. Serial studies were analyzed by an independent echocardiography core laboratory for aortic and mitral valve structure and function, and left ventricular ejection fraction (LVEF). During Impella support, there was no appreciable change in the degree of baseline valvular regurgitation. Additionally, there were no cases of structural derangement of the mitral or aortic valve after the use of the Impella device. At 90-day follow-up, there was an average 22% relative increase in LVEF from baseline (27% ± 9 vs. 33% ± 11, P < 0.001).

- **Conclusions**: The present echocardiographic analysis of the PROTECT II study confirms prior observations regarding the safety of the Impella 2.5 device with respect to mitral and aortic valve function.

---

### Percutaneous aortic valve replacement: an experimental study. I. Studies on implantation [^117RtPHv]. The Journal of Thoracic and Cardiovascular Surgery (2002). Low credibility.

The purpose of this preliminary study was to devise a new surgical procedure for minimally invasive aortic valve implantation with a transluminal technique.

- **Methods**: The new collapsible heart valve was prepared by mounting a porcine aortic valve, taken from a freshly slaughtered pig, into a self-expandable nitinol stent by means of a suture technique. The outer diameter of the valved stent ranged from 15 to 23 mm, and the length ranged from 21 to 28 mm. Before implantation in vivo, these valved stents were tested in an in vitro circulatory system. Only in vitro-tested valved stents with a pressure gradient of less than 7 mm Hg and regurgitation of I degrees or less were used for transluminal aortic valve implantation in vivo. Six of these valved stents were implanted in the descending aorta and eight in the ascending aorta of anesthetized pigs. The catheter delivery system (22F) was extraperitoneally inserted through the left iliac artery or the infrarenal aorta. Measurements for transvalvular gradient, valvular opening and closure, blood-flow characteristics, regurgitation, and macroscopic analysis were performed at baseline and after the observation period (164 ± 48 minutes).

- **Results**: This preliminary study contained 14 animals. One animal died of ventricular fibrillation. Technical failure occurred in two pigs as a result of stent twisting. At the end of the observation period, the 11 successfully implanted valved stents demonstrated low transvalvular gradients (mean end-systolic Deltarho(max) of 5.4 ± 3.3 mm Hg for the descending aorta group, 5.4 ± 1.2 mm Hg).

---

### Different applications for left ventricular mechanical support with the Impella Recover 100 microaxial blood pump [^11177n3Q]. The Journal of Heart and Lung Transplantation (2005). Low credibility.

The "Impella Recover 100" (IR100) is a new intravascular microaxial blood pump used for short-term mechanical support in cases of acutely reduced left ventricular function. From September 2002 to April 2003, we used the IR100 to support five patients: two patients were bridged to heart transplant, two were treated for fulminant acute myocarditis, and one for post-cardiotomy low-output syndrome. Only one patient with myocarditis died of septic shock; two had successful heart transplants; and the latter two were slowly weaned from the device and, at 3-month follow-up, showed moderate improvement of left ventricular (LV) function. Our initial experience with the IR100 as mechanical support for patients in cardiogenic shock of varying etiology has been positive, yielding good survival in a population of particularly compromised patients.

---

### Impella RP in the treatment of right ventricular failure: What we know and where we go [^115YyL85]. Journal of Cardiothoracic and Vascular Anesthesia (2018). Low credibility.

Temporary mechanical circulatory support devices for the treatment of acute right ventricular failure represent crucial tools for clinical practice. Right ventricular failure presents specific treatment issues, and dedicated percutaneous devices are fewer in number compared to those for the left ventricle. Data and insights on mechanical circulatory support for the right ventricle come mostly from the context of cardiac surgery, predominantly in the setting of acute right ventricular failure after left ventricular assist device implantation.

The Impella RP (Abiomed, Danvers, MA) is a minimally invasive temporary device that has gained application for the percutaneous treatment of right ventricular failure with positive clinical results. Even though treatment indications are clear, technical and management issues remain relevant due to the limited scientific data available. Appropriate positioning and repositioning, interaction with the right ventricular valvular apparatus, anticoagulation management, weaning, and patient mobilization are examples of the ongoing challenges. In line with the positive initial experience with this device, future research efforts should focus on improving device limitations and providing additional data that might drive optimal clinical management.

---

### The management of cardiogenic shock from diagnosis to devices: A narrative review [^115coa1p]. CHEST Critical Care (2024). Low credibility.

The Impella (Abiomed, Inc.) is a percutaneously implanted, transvalvular, axial flow pump. Axial flow is produced by an impeller that traverses the aortic valve and expels blood from the left ventricle (LV) into the ascending aorta. The two available models for LV support are Impella CP, which provides up to 4 L/min of flow, and Impella 5.5, which provides up to 5.5 L/min of flow. The Impella CP is inserted femorally via a 14-F sheath, whereas the Impella 5.5 is inserted via a 23-F sheath through a surgical axillary cutdown and graft. Hemodynamically, the Impella directly unloads the LV and augments cardiac output (CO), reducing wall stress, end-diastolic pressure, and volume.

Limitations of the Impella include access site complications resulting from large-bore cannulation, as well as significant risk for hemolysis, with associated renal failure, and thrombocytopenia, especially with the Impella CP. Impella placement requires fluoroscopy and, in the case of the Impella 5.5, surgical cutdown and graft anastomosis; thus, the Impella typically is not an option for emergent bedside placement.

It is the opinion of the authors that, given the modest CO support and high rates of hemolysis and kidney injury, the Impella CP is no longer considered to be an adequate longitudinal shock device at many shock referral centers. Instead, the axillary-placed Impella 5.5, which also enables ongoing rehabilitation before heart replacement therapy, is preferred for more sustained support.

In patients with acute myocardial infarction-cardiogenic shock (AMI-CS), the Impella was compared with the intra-aortic balloon pump (IABP) in the "Impella vs. IABP Reduces Mortality in ST" study.

---

### CT and chest radiography in evaluation of mechanical circulatory support devices for acute heart failure [^113wvUkj]. Insights into Imaging (2023). High credibility.

The Impella LV support system is a catheter-based miniaturized ventricular assist device by Abiomed Inc. (MA, USA) that pumps blood from the left ventricle (LV) into the ascending aorta. This continuous flow device draws blood from the inlet port in the LV and expels it into the ascending aorta via the outlet port. The US Federal Drug Authority (FDA) has authorized the emergency use of the Impella LV support systems for temporary LV unloading and support, specifically ≤ 4 days for Impella 2.5, Impella CP, and Impella CP with SmartAssist; and ≤ 14 days for Impella 5.0 and Impella 5.5 with SmartAssist.

There are two Impella devices primarily in use for LV support: Impella CP, which is placed percutaneously and provides flow up to 4.4 L/min; and Impella 5.5, which provides flow up to 6 L/min and requires surgical implantation via a 10-mm vascular graft sewn to either the axillary artery or the ascending aorta. The Impella catheter connects to the console, which displays rotations per minute, flow parameters, and aortic and LV pressures. The use of the Impella device can be associated with higher rates of adverse events and increased costs.

In the PROTECT-II study, a prospective, multicenter randomized controlled trial, 452 patients undergoing high-risk PCI were randomly assigned to intra-aortic balloon pump (IABP) or Impella 2.5. The study found no difference in 30 or 90-day adverse cardiovascular events but did observe lower adverse events at 90 days in the Impella 2.5 arm.

---

### Transinnominate Impella 5.5 insertion as a bridge to transplantation in a pediatric patient in refractory cardiogenic shock [^1122dpUC]. JTCVS Techniques (2022). Low credibility.

An upper partial sternotomy was performed into the third intercostal space (Figure 1, A). The innominate vein was retracted inferiorly to facilitate exposure of the innominate artery while leaving the pericardium intact. Care was taken to avoid injury to the right recurrent laryngeal nerve. After the administration of 5000 units of intravenous heparin, the innominate artery was clamped and opened (Figure 1, B). A 10-mm Gelweave graft (Vascutek) was sewn end-to-side onto the artery using 5–0 PROLENE. The graft was tunneled out to the supraclavicular space (Figure 1, C), and the Impella was introduced through the graft over a guidewire and positioned into the LV under fluoroscopic and TEE guidance (Figure 1, D). Following TEE confirmation of inflow position approximately 4.5 cm from the aortic valve annulus, the Impella was turned on and increased to a performance level of P7, providing 4 L/min of flow. Right heart catheterization demonstrated a reduction in PCWP to 17 mm Hg. The graft was trimmed, and the silicon plug was placed at skin level. After securing the device to the graft with multiple silk ties, the covering sheath was advanced and secured to the graft and skin. A mediastinal chest tube was placed before chest closure.

- **Procedural steps for transinnominate Impella 5.5 insertion**:
	- A, Upper partial sternotomy into the third intercostal space. B, The innominate artery is dissected and controlled proximally and distally before arteriotomy. Note that the pericardium is left completely intact. C, A Gelweave graft is sewn end-to-side onto the artery and then tunneled out.

---

### 2020 ACC/AHA guideline for the management of patients with valvular heart disease: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines [^111DvtPo]. The Journal of Thoracic and Cardiovascular Surgery (2021). High credibility.

Regarding surgical interventions for aortic stenosis, more specifically with respect to aortic valve replacement (choice of valves), ACC/AHA 2021 guidelines recommend considering performing aortic valve replacement by a pulmonic autograft (the Ross procedure) at a comprehensive valve center in patients under 50 years of age with appropriate anatomy, who prefer bioprosthetic aortic valve replacement.

---

### 2020 ACC/AHA guideline for the management of patients with valvular heart disease: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines [^1151D4JR]. The Journal of Thoracic and Cardiovascular Surgery (2021). High credibility.

Regarding surgical interventions for aortic stenosis, more specifically with respect to aortic valve replacement, the ACC/AHA 2021 guidelines recommend performing aortic valve replacement in adult patients with severe high-gradient AS (stage D1) and symptoms of exertional dyspnea, HF, angina, syncope, or presyncope by history or on exercise testing.

---

### Relationship of normal aortic valve cusp dimensions: A tool to optimize cusp reconstruction valvuloplasty [^117GDtz4]. Seminars in Thoracic and Cardiovascular Surgery (2015). Low credibility.

Outcomes of surgical aortic valvuloplasty hinge primarily on optimal leaflet design. Imprecise valve reconstruction can result in insufficiency or stenosis. Predicting postrepair leaflet parameters from pre- or intraoperative readily measurable valve dimensions could result in improved reconstruction. This study analyzes the relationships between different parameters of the normal aortic valve to establish a method of deriving the optimal dimensions of the reconstructed leaflet following valvuloplasty.

Morphologic analysis of the normal aortic valve was performed on 50 autopsy specimens. The following parameters were measured: circumference at the ventriculoaortic junction, intercommissural circumferential distance (IC), commissural height, leaflet free-margin length (L1-length of the free margin of each leaflet), cusp attachment length (L2-cusp attachment length at the ventriculoaortic junction), and leaflet height (A, i.e. the vertical or cephalocaudal distance along the convex surface of the leaflet from the midpoint of the leaflet free margin to the midpoint of the cusp attachment). Univariate linear regression analysis was used to test the interdependence of leaflet dimensions.

The leaflet free-margin length L1 correlated strongly with the corresponding IC: r = 0.74, 0.81, and 0.79 for noncoronary, right coronary, and left coronary leaflets, respectively; P = 0.000. Leaflet height A and cusp attachment length L2 also correlated well with the corresponding IC: A-IC, r = 0.56, 0.74, and 0.66; and L2-IC, r = 0.78, 0.85, and 0.80 for noncoronary, right coronary, and left coronary leaflets, respectively.

---

### Novel fluoroscopic evaluation of incorrect Impella placement [^1124pi6f]. Catheterization and Cardiovascular Interventions (2025). Low credibility.

A 65-year-old man with newly diagnosed cardiomyopathy was found to have multivessel coronary artery disease. After he was deemed not to be a surgical candidate, Impella-supported percutaneous coronary intervention was successfully performed on his left main and left circumflex arteries. Although initially thought to be in the correct position by standard single-plane fluoroscopy, the Impella catheter was shown, with the use of additional non-standard fluoroscopic views, to be oriented toward the mitral apparatus. Malrotation of the Impella microaxial flow pump catheter can lead to complications and suboptimal unloading. This case highlights a novel fluoroscopic technique for evaluation of incorrect Impella placement.

---

### Treatment with Impella increases the risk of de novo aortic insufficiency post left ventricular assist device implant [^113LEshH]. Journal of Cardiac Failure (2020). Low credibility.

Impella (Abiomed Inc, Danvers, MA) is a temporary mechanical support device positioned across the aortic valve and can be used to support patients before LVAD implantation. There are no data on the incidence of aortic insufficiency (AI) in patients supported with Impella as a bridge to durable LVAD implantation. We sought to assess the incidence of AI in patients with Impella support as a bridge to durable left ventricular assist device (LVAD) implantation.

- **Methods**: We reviewed all patients undergoing primary LVAD implantation at the University of Pennsylvania from January 2015 onward, comparing those supported with Impella as temporary mechanical support with those supported by either venoarterial extracorporeal life support or an intra-aortic balloon pump. We reviewed transthoracic echocardiography preoperatively, as well as at 1 week, 1, 3, 6, 9, and 12 months after LVAD implantation.

- **Results**: A total of 215 echocardiograms were analyzed in 41 patients. Eleven patients were supported with Impella before LVAD implant — 6 patients with Impella alone (5 with Impella CP, 1 with Impella 5.0) and 5 with Impella in conjunction with venoarterial extracorporeal life support (2 with Impella 2.5, 2 with Impella CP, and 1 with Impella 5.0). After LVAD implant, mild or moderate AI developed in 82% of patients supported with Impella (9 of 11) compared with 43% of those without Impella (13 of 30) (P = 0.038).

- **Conclusions**: Patients supported by Impella as a bridge to durable LVAD have a higher risk of developing AI. Further studies are needed to assess this risk as the use of Impella in such contexts increases.

---

### 2020 ACC/AHA guideline for the management of patients with valvular heart disease: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines [^113ZrAs7]. The Journal of Thoracic and Cardiovascular Surgery (2021). High credibility.

Regarding surgical interventions for aortic stenosis, specifically concerning aortic valve replacement, the ACC/AHA 2021 guidelines recommend considering aortic valve replacement in apparently asymptomatic patients with severe AS (stage C1) and low surgical risk if the serum BNP level is more than three times the normal level.

---

### Surgically implanted endovascular, microaxial left ventricular assist device: A single institution study [^1138T4Hi]. JTCVS Techniques (2024). Low credibility.

Survival after implantation of the Impella 5.5 is varied and depends on the indication for use. The treatment of cardiogenic shock (CS) and high-risk cardiogenic shock (HRCS) has evolved with the introduction of the Impella 5.5. We present a large, single-center case series describing outcomes with this device.

Prior to the introduction of the Impella 5.0 and Impella 5.5 (Abiomed, Inc.), options for temporary left ventricular support included an intra-aortic balloon pump (IABP), a temporary central ventricular assist device, the Impella 2.5 or CP (Abiomed, Inc.), the TandemHeart (LivaNova), or venoarterial extracorporeal membrane oxygenation (VA-ECMO). The Impella 5.5 received US Food and Drug Administration approval in October 2019, thereby expanding the treatment options for heart failure and cardiogenic shock.

The Impella 5.5 is a microaxial left ventricular assist device (LVAD) that can be implanted through a graft surgically attached to the axillary artery or aorta. The inlet is positioned in the left ventricle and the outlet in the ascending aorta, traversing the aortic valve. It can deliver up to 5.5 L/min of blood flow and is approved by the Food and Drug Administration for up to 14 days of use, although it has been utilized for longer periods in clinical settings.

Recent publications have examined the safety and short-term outcomes of this device. These studies are mostly limited to small, single-center case series, as well as larger multi-institutional, industry-driven studies. Consequently, we aim to provide a detailed description of the outcomes observed.

---

### Effectiveness of an Impella versus intra-aortic balloon pump in patients who received extracorporeal membrane oxygenation [^1167YBuy]. Journal of the American Heart Association (2025). High credibility.

Drs Nishimoto and Nakata received lecture fees from Abiomed Japan. The remaining authors have no disclosures to report.

---

### Improved technique of transapical aortic valve implantation: "The Berlin addition" [^112MK6Lu]. The Annals of Thoracic Surgery (2010). Low credibility.

Transapical aortic valve implantation carries some degree of uncertainty regarding the definitive valve position. We added angiographic visualization of the aortic root while the prosthetic valve is being slowly deployed. This enables easy correction of the valve position to achieve perfect alignment of the relationships between the prosthetic valve, aortic valve annulus, aortic cusps, and the coronary arteries.

---

### Best practices of aortic valve replacement with the Edwards Intuity Elite valve [^114G1GGb]. The Annals of Thoracic Surgery (2020). Low credibility.

The Edwards Intuity Elite (EIE; Edwards Lifesciences, Irvine, CA) valve system is a recent surgical aortic valve designed to expedite implantation, facilitate minimally invasive approaches, and provide low gradients, particularly in smaller valve sizes. The report reviews various best practices learned through experience with the EIE valve system.

- **Description**: With its sealing frame designed to anchor and seal the valve after resection of the diseased native aortic valve, EIE use differs from that of conventional sutured valves.

- **Evaluation**: Critical technical aspects include patient selection, aortotomy and debridement, valve sizing, guiding suture technique, and valve seating and deployment. In addition, special anatomic and pathologic conditions are considered, as well as intraoperative transesophageal echocardiography and postimplantation cardiac rhythm monitoring.

- **Conclusions**: These best practices simplify and standardize the use of the EIE valve system and may benefit surgeons adopting this valve.

---

### Left ventricular perforation after Impella® placement in a patient with cardiogenic shock [^117KBFhH]. Catheterization and Cardiovascular Interventions (2018). Low credibility.

Mechanical cardiovascular support devices are now widely used both in the setting of cardiogenic shock and during high-risk cardiac catheterization procedures. We report a case of a young female patient who presented with presumed myocarditis and rapidly deteriorating decompensated heart failure, requiring the implantation of an Impella Circulatory Support System. Upon transfer to our facility, it was discovered that during transport, the Impella device had migrated through the left ventricle. She was emergently taken to the operating room where the Impella was surgically removed and biventricular support devices were placed. The patient eventually expired after weeks of treatment in the intensive care unit. We believe this is the first recorded case of an Impella device perforating the left ventricle.

Particularly in cases of newly discovered pericardial effusion, change in waveform on the Impella controller placement signal, or rapid decompensation, physicians should consider this rare but potentially catastrophic complication associated with mechanical left ventricular support devices.

---

### Advantages of intraoperative implantation of Impella 5.5 SmartAssist in the management of acute post-infarction ventricular septal defect with cardiogenic shock [^112UFuKx]. Journal of Cardiothoracic Surgery (2021). Low credibility.

With a forward flow to the systemic circulation of up to 6.2 L/min, the Impella 5.5 is best able to decompress the heart of all currently available mechanical circulatory support devices used in the setting of cardiogenic shock. This is particularly important in patients with large body habitus or in cardiogenic shock with a vasodilatory component, which may be exacerbated by suboptimal LV decompression. Other features of the Impella 5.5 SmartAssist include the potential for device removal and repositioning at bedside. Furthermore, in our cases, we observed an improvement in RV function with resolution of pulmonary edema. These findings may lower the decision threshold for an early surgical approach and the initiation of mechanical circulatory support, restoring the hemodynamics, preventing the aggravation of organ failure, and potentially leading to improved outcomes in patients with post-infarction VSD in cardiogenic shock.

---

### Comparison of latest generation intra- and supra-annular self-expanding transcatheter heart valves for aortic valve-in-valve procedures [^114VJCwk]. Catheterization and Cardiovascular Interventions (2025). Low credibility.

Limitations for a retrospective single-center study apply, including small sample size and absence of patient randomization, which may introduce bias by hidden confounders. However, the potential impact of learning curves should be limited, as patients from both the study and control groups were treated during the same period and no significant baseline differences were observed. Therefore, results should be interpreted with caution and outcomes should be evaluated in larger populations.

---

### Successful echocardiography-guided medical management of severe early post-implant right ventricular failure in a patient with left ventricular assist device support: a case report [^117Gsipf]. Journal of Cardiothoracic Surgery (2023). Low credibility.

Recently, Impella RP (Abiomed, Danvers, Mass. USA) was reported to support the RV in patients with post-implant LVAD. It might be a useful tool for patients who have subclinical or mild RVF and in whom RVAD might be excessive treatment.

In conclusion, early detection, together with both proper and prompt medical management, is crucial to avoiding surgical intervention in the management of post-implant RHF. Further, close observation of the echocardiogram might be helpful in detecting subclinical early post-implant RHF and for daily medication assessment.

---

### 2020 ACC/AHA guideline for the management of patients with valvular heart disease: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines [^115mvvQ8]. The Journal of Thoracic and Cardiovascular Surgery (2021). High credibility.

Regarding surgical interventions for aortic stenosis, particularly concerning aortic valve replacement, the ACC/AHA 2021 guidelines recommend considering aortic valve replacement in asymptomatic patients with severe high-gradient aortic stenosis (stage C1) and a progressive decrease in left ventricular ejection fraction on at least three serial imaging studies to below 60%.

---

### Impella 5.5 direct aortic implant and explant techniques [^112pCj1a]. The Annals of Thoracic Surgery (2021). Low credibility.

The Impella 5.5 with SmartAssist system (Abiomed, Danvers, MA) is approved for the treatment of cardiogenic shock after acute myocardial infarction, cardiac surgery, or in the setting of cardiomyopathy. Designed for full circulatory support and left ventricular unloading, the system comprises a catheter-based microaxial pump placed across the aortic valve, pulling blood from the left ventricle and into the ascending aorta. Implantation can be approached through the axillary artery or directly into the aortic root. We present several technical options for implanting, tunneling, and explanting the system using the direct aortic approach, allowing for bedside removal.

---

### Percutaneous transvalvular microaxial flow pump support in cardiology [^1135GFxz]. Circulation (2022). Low credibility.

The Impella device (Impella, Abiomed, Danvers, MA) is a percutaneous transvalvular microaxial flow pump currently used for (1) cardiogenic shock, (2) left ventricular unloading (combination of venoarterial extracorporeal membrane oxygenation and Impella concept), (3) high-risk percutaneous coronary interventions, (4) ablation of ventricular tachycardia, and (5) treatment of right ventricular failure. Impella-assisted forward blood flow increased mean arterial pressure, cardiac output, peripheral tissue perfusion, and coronary blood flow in observational studies and some randomized trials. However, due to the need for large-bore femoral access (14 F for the commonly used Impella CP device) and anticoagulation, incidences of bleeding and ischemic complications are as much as 44% and 18%, respectively. Hemolysis is reported in as many as 32% of patients and stroke in as many as 13%.

Despite the rapidly growing use of the Impella device, there are still insufficient data on its effect on outcome and complications based on large, adequately powered randomized controlled trials. The only two small and underpowered randomized controlled trials in cardiogenic shock comparing Impella versus intra-aortic balloon pump did not show improved mortality. Several larger randomized controlled trials are currently recruiting patients or are in preparation for cardiogenic shock — DanGer Shock [Danish-German Cardiogenic Shock Trial; NCT01633502], left ventricular unloading — DTU-STEMI [Door-To-Unload in ST-Segment-Elevation Myocardial Infarction; NCT03947619].

---

### 2020 ACC/AHA guideline for the management of patients with valvular heart disease: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines [^115F6wRB]. The Journal of Thoracic and Cardiovascular Surgery (2021). High credibility.

Regarding surgical interventions for aortic stenosis, specifically aortic valve replacement, the ACC/AHA 2021 guidelines recommend performing aortic valve replacement in symptomatic patients with low-flow, low-gradient severe AS with reduced LVEF (stage D2).

---

### Improved clinical outcomes associated with the Impella 5.5 compared to the Impella 5.0 in contemporary cardiogenic shock and heart failure patients [^116JLiFM]. The Journal of Heart and Lung Transplantation (2023). High credibility.

A redesigned, surgically implanted heart pump incorporates several design changes from the prior device generation, but no published comparative data demonstrate if these changes translate to improved outcomes. We retrospectively compared clinical characteristics and outcomes, drawn from an FDA-mandated QA database, for contemporary patients treated with the Impella 5.5 or Impella 5.0 for acute myocardial infarction complicated by cardiogenic shock (AMICS), cardiomyopathy, or postcardiotomy cardiogenic shock (PCCS).

A total of 1,238 patients at 290 US sites were included for analysis. Patients receiving the Impella 5.5 had significantly higher survival through explant (i.e. successfully weaned or bridged to heart replacement therapy) than those receiving the Impella 5.0 in all three settings: AMICS (70.5% vs. 56.8%; p = 0.005), cardiomyopathy (88.1% vs. 76.9%; p = 0.001), and PCCS (76.1% vs. 55.7%; p = 0.003). Duration of support was significantly longer for Impella 5.5 patients with AMICS (9.2 vs. 6.1 days; p = 0.008) and cardiomyopathy (10.7 vs. 8.1 days; p < 0.001).

---

### 2020 ACC/AHA guideline for the management of patients with valvular heart disease: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines [^115ogXeR]. The Journal of Thoracic and Cardiovascular Surgery (2021). High credibility.

Regarding medical management for prosthetic heart valves, and specifically concerning anticoagulant therapy after surgical mechanical prosthesis implantation, the ACC/AHA 2021 guidelines recommend considering the initiation of VKAs to achieve a lower INR (1.5–2.0). This should start ≥ 3 months after surgery, with the continuation of aspirin 75–100 mg/day, in patients with a mechanical On-X aortic valve replacement and no thromboembolic risk factors.

---

### Impella placement guided by echocardiography can be used as a strategy to unload the left ventricle during peripheral venoarterial extracorporeal membrane oxygenation [^115RwSEs]. Journal of Cardiothoracic and Vascular Anesthesia (2018). Low credibility.

At the authors' institution, before 2015, patients cannulated for peripheral venoarterial extracorporeal membrane oxygenation (VA-ECMO) did not undergo left ventricular (LV) decompression with the use of an LV vent. After 2015, the authors' institution began using the Impella device to vent the left ventricle in patients on VA-ECMO. The authors hypothesized that survival outcomes would improve in patients on VA-ECMO with the use of an Impella for LV venting.

- **Design**: Retrospective, chart-based review study.

- **Setting**: Single center, university-based hospital.

- **Participants**: All adult patients at the authors' institution who required VA-ECMO between January 2015 and May 2017.

- **Intervention**: An Impella (Abiomed, Danvers, MA) device was placed percutaneously in patients cannulated for VA-ECMO as a mechanism to provide LV venting and decompression, therefore unloading the heart.

- **Measurements and main results**: Manual chart review was conducted, and a survival analysis was performed. It was observed that patients on VA-ECMO in whom an Impella was implanted had improved survival and an improvement in LV function as demonstrated by echocardiography compared with patients maintained on VA-ECMO alone.

Conclusions indicate that patients on VA-ECMO plus Impella implantation demonstrated improved survival compared with patients treated with VA-ECMO alone. Key echocardiographic characteristics such as improved LV function after Impella placement and LV cavity size reduction during therapy may help predict those patients who may benefit most from this cannulation strategy.

---

### Perforation of the anterior mitral leaflet after Impella LP 5.0 therapy in cardiogenic shock [^111AhM7f]. The American Journal of Cardiology (2016). Low credibility.

A 52-year-old man was admitted with out-of-hospital cardiac arrest, and he was resuscitated after 100 minutes. The initial hemodynamic condition was critical due to cardiogenic shock, with a left ventricular ejection fraction of 10% and a mean arterial pressure of 60 mmHg on inotropics. Acute coronary angiography did not reveal any new lesions. Due to persistent hemodynamic instability, mechanical support with Impella LP 5.0 was decided upon. The surgical procedure, guided by fluoroscopy and transesophageal echocardiography, was uncomplicated. Hemodynamics improved subsequently, and after 17 days of intensive care and an additional 30 days of hospitalization, the patient was ready for discharge.

Routine echocardiography prior to discharge revealed severe mitral regurgitation due to the perforation of the anterior mitral leaflet, a finding not observed in previous echocardiograms. The patient was discharged to close follow-up of the severe mitral regurgitation, and future surgical intervention is likely. Therefore, close monitoring of the mitral valve is necessary, and intervention may be required if valve dysfunction is observed, as repositioning of the Impella system is not possible.

---

### Complications leading to death in patients supported by the Impella 5.5: Analysis from the FDA MAUDE database [^111sHozh]. Catheterization and Cardiovascular Interventions (2025). Low credibility.

This study identifies procedural-related complications as the leading cause of death in patients supported by the Impella 5.5, with cardiac perforation being the most frequent. Improper placement or re-positioning of the device within the left ventricle emerged as a critical factor. Other procedural challenges, such as bleeding, vessel dissection, and graft detachment, underscore the technical complexities involved in device placement, particularly in patients with challenging anatomies or fragile cardiac tissue.

One contributing factor may be limited training and inexperience regarding the best techniques for placement, re-positioning, or removal of the Impella 5.5. As the device was recently introduced, many facilities are still in the process of developing procedural expertise. Therefore, increased practical experience may be necessary to master its proper manipulation and minimize complications. Additionally, anatomical variability — such as differences in ventricular or vessel sizes and tissue fragility — can further complicate the standardization of the procedure. For instance, one reported case described how vessel size changes created difficulties during device removal. Similarly, several cases attributed cardiac perforation to friable cardiac tissue, which ultimately led to patient deaths.

Complications among 43 cases were categorized as device-related, procedural, or unknown causes, with procedural complications being the most common.